QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 nkgen-biotech-presents-new-snk01-biomarker-data-at-the-2024-aaic-held-on-july-30-2024

SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) p...

 why-nkgen-biotech-nkgn-stock-is-skyrocketing

NKGen Biotech shares are trading higher by 32.5% Thursday morning. The company announced it will present new SNK01 biomarker da...

Core News & Articles
Market-Moving News for July 18th
07/18/2024 12:28:09

NKGN: 88% | NKGen Biotech Will Present New Biomarker Data On SNK01 In Alzheimer's Disease During A Poster Presentation At T...

 nkgen-biotech-will-present-new-biomarker-data-on-snk01-in-alzheimers-disease-during-a-poster-presentation-at-the-upcoming-alzheimers-association-international-conference-from-july-28--august-1

NKGen will present data on SNK01's ability to reduce α-synuclein in Alzheimer's patients, which is significant given th...

 why-nkgen-biotech-stock-is-moving-higher-monday

NKGen Biotech shares are trading higher Monday after the company's SNK01 NK Cell Therapy was cleared to begin a Phase 2 tri...

Core News & Articles
Market-Moving News for May 20th
05/20/2024 12:37:59

PTCT: 27% | PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation NKGN: 81% | NK...

Core News & Articles
Market-Moving News for April 29th
04/29/2024 12:46:23

TSLA: 14% | Tesla shares are trading higher on reports the company will partner with Baidu for mapping and navigation for Full ...

 nkgen-biotech-announces-fda-clearance-of-ind-application-for-snk01-nk-cell-therapy-in-parkinsons-disease

NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION